Having trouble accessing articles? Reset your cache.

Bladder cancer data poise FerGene gene therapy to compete with Keytruda

Less than two weeks after its launch, Ferring’s gene therapy subsidiary has revealed data that suggest its nadofaragene firadenovec could compete with Keytruda in an early form of bladder cancer.

The adenovirus serotype 5 vector delivering IFNA2B appears to be at least as efficacious as the anti-PD-1 mAb from Merck &

Read the full 506 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE